• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Restasis (cyclosporine ophthalmic emulsion)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Restasis (cyclosporine ophthalmic emulsion)

  • Profile

Profile

Contact Information

Contact: Allergan, an AbbVie Company
Website: www.restasis.com

Currently Enrolling Trials

    Show More

    General Information

    Restasis (cyclosporine emulsion) 0.05% is a calcineurin inhibitor immunosuppressant.

    Restasis is specifically indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. 

    Restasis is supplied as an ophthalmic emulsion. Instill one drop of Restasis ophthalmic emulsion twice a day in each eye approximately 12 hours apart.

    Mechanism of Action

    Restasis (cyclosporine ophthalmic emulsion) 0.05% contains a topical immunomodulator with anti-inflammatory effects. Cyclosporine, a fine white powder, is an immunosuppressive agent when administered systemically. Cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.

    Evidence indicates that inflammation of both the lacrimal gland and ocular surface is at the root of keratoconjunctivitis sicca, commonly referred to as dry eye disease. Restasis helps to reduce that inflammation.

    Side Effects

    Adverse events associated with the use of Restasis may include (but are not limited to) the following:

    • Ocular Burning
    • Conjunctival Hyperemia
    • Discharge
    • Epiphora
    • Eye Pain
    • Foreign Body Sensation
    • Pruritus
    • Stinging
    • Visual Disturbance

    Clinical Trial Results

    Approval of Restasis is based on four multicenter, randomized, clinical studies performed in approximately 1,200 patients with moderate to severe keratoconjunctivitis sicca.

    Restasis demonstrated statistically significant increases in Schirmer wetting of 10 mm versus vehicle at six months in subjects whose tear production was presumed to be suppressed due to ocular inflammation. Data showed that 15% of subjects treated with Restasis showed increased tear production compared to 5% of vehicle treated patients. No increase in tear production was observed in subjects being treated with anti-inflammatory drugs or using punctal plugs.

    Approval Date: 2002-12-01
    Company Name: Allergan, an AbbVie Company
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing